Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
Keel Pharmaceuticals, Inc.
Download detailed PDF Members: Keel Pharmaceuticals, Inc. is a private biopharmaceutical company that is developing new therapies to treat type 1 diabetes and other autoimmune diseases. Keels technology is based on the identification of specific protein processing and signalling defects present in the autoreactive white blood cells (lymphocytes) that cause autoimmune diseases. The identification of these defects has yielded a proprietary approach to the treatment of autoimmunity based on selective destruction of auto reactive lymphocytes and re-establishment of immune tolerance. Current therapies for autoimmune diseases and the majority of therapies under development target either the biochemical by-products of autoimmune diseases or classes of lymphocytes generally (i.e., whether they are autoreactive or not). By treating the causes of autoimmunity directly, Keels therapies have the potential to provide patients with long-lasting relief from disease and, perhaps, permanent reversal.
This page has been viewed 969 times since April 2007, the link to the organisation's website has been followed 226 times Recent Search Terms used to find this page: keel pharmaceuticals | zeel Pharmaceuticals email | keel pharmaceuticals | Keel Pharmaceuticals | keel pha | Keel Pharmaceuticals | keel ph | keel pharmaceuticals | keel pharmaceuticals | zeel | . Search for more companies in Cambridge Search for more companies in Massachusetts This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Keel Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||||||||
|